Skip to main content

FDA rejects Intarcia's drug pump

The FDA sent bad news to Intarcia Therapeutics, rejecting aspects of its manufacturing plan for a matchstick-sized drug pump for the treatment of Type 2 diabetes.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.